Mylan Receives Approval on Lovastatin Tablets

Business Wire, June 18, 2001

Business/Medical Editors

PITTSBURGH--(BUSINESS WIRE)--June 18, 2001

Mylan Laboratories Inc. (NYSE:MYL) announced today that the Food and Drug Administration has approved its abbreviated new drug application (ANDA) for Lovastatin Tablets in 10 mg, 20 mg, and 40 mg strengths.

Lovastatin is the generic equivalent to Merck's cholesterol lowering agent Mevacor(R).

The product will be manufactured in Mylan's Morgantown, West Virginia facility and shipped in July.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription pharmaceutical products. The Company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through its Bertek Pharmaceuticals Inc. subsidiary. These products are manufactured and sold in a variety of dosage forms including immediate and extended-release oral tablets and capsules and transdermal patches as well as repackaging and marketing multi-source and single-source products in unit dose form. For more information, visit www.mylan.com.